The case of methotrexate and the lung: Dr Jekyll and Mr Hyde
- PMID: 33574052
- DOI: 10.1183/13993003.00079-2021
The case of methotrexate and the lung: Dr Jekyll and Mr Hyde
Conflict of interest statement
Conflict of interest: V. Cottin has received fees for consultancy from Actelion, Boehringer Ingelheim, Bayer, Biogen Idec, GSK, MSD, Novartis, Roche, Sanofi and Galapagos; has received lecture fees from Actelion, Boehringer Ingelheim, Novartis, Roche and Sanofi; has received reimbursement for travel to medical meetings from Actelion, Boehringer Ingelheim and Roche; has received fees for development of educational presentations from Boehringer Ingelheim; has acted as a member of an adjudication committee for Gilead; has received grants to his institution from Boehringer Ingelheim and Roche; and has acted as a member of data and safety monitoring boards for Promedior, Celgene and Galecto. Conflict of interest: E. Bendstrup has nothing to disclose. Conflict of interest: P. Bonniaud has nothing to disclose. Conflict of interest: M. Nasser has nothing to disclose. Conflict of interest: P. Spagnolo has nothing to disclose. Conflict of interest: C. Valenzuela has nothing to disclose. Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape
Comment on
-
Methotrexate and rheumatoid arthritis associated interstitial lung disease.Eur Respir J. 2021 Feb 11;57(2):2000337. doi: 10.1183/13993003.00337-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 32646919 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources